First-generation HIV-1 protease inhibitors for the treatment of HIV/AIDS

Aspartic Acid Proteases as Therapeutic Targets

Volumn 45, Issue , 2011, Pages 139-168

  Virgil, Scott C ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Amprenavir; Indinavir; Nelfinavir; Protease inhibitor; Ritonavir; Saquinavir

Indexed keywords

EID: 84974630547     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630943.ch6     Document Type: Chapter

References (94)

1. Kohl, N.E., Emini, E.A., Schleif, W.A., Davis, L.J.,Heimbach, J.C., Dixon, R.A.F., Scolnick, E.M., and Sigal, I.S. (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proceedings of the National Academy of Sciences of the United States of America, 85, 4686-4690.
2. Huff, J.R. (1991) HIV protease: a novel chemotherapeutic target for AIDS. Journal of Medicinal Chemistry, 34, 2305-2314.
3. Lunney, E.A. and Humblet, C. (1998) Structure-based design: from renin to HIV protease, in Structure-Based Ligand Design (eds K. Gubernatorand H.-J. Bohm), Wiley-VCH Verlag GmbH, pp. 36-69.
4. Navia, M.A., Fitzgerald, P.M.D., McKeever, B.M., Leu, C.-T., Heimbach, J.C., Herber,W.K., Sigal, I.S., Darke, P.L., and Springer, J.P. (1989) Threedimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature, 337, 615-620;
5. Wlodawer, A., Miller, M., Jaskólski, M., Sathyanarayana, B.K., Baldwin, E.,Weber, I.T., Selk, L.M., Clawson, L., Schneider, J., and Kent, S.B.H. (1989) Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science, 245, 616-621;
6. Lapatto, R., Blundell, T., Hemmings, A., Overington, J., Wilderspin, A.,Wood, S.,Merson, J.R., Whittle, P.J., Danley, D.E., Geoghegan, K.F., Hawrylik, S.J., Lee, S.E., Scheld, K.G., and Hobart, P.M. (1989) X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature, 342, 299-302.
7. Kumar, M., Prashar, V., Mahale, S., and Hosur, M.V., (2005) Observation of a tetrahedral reaction intermediate in the HIV-1 protease-substrate complex. The Biochemical Journal, 389, 365-371;
8. Kovalevsky, A.Y., Chumanevich, A.A., Liu, F., Louis, J.M., andWeber, I.T. (2007) Caught in the act: the 1.5 A resolution crystal structure of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry, 46, 14854-14864.
9. Hyland, L.J., Tomaszek, T.A., Jr., Roberts, G.D., Carr, S.A., Magaard, V.W., Bryan, H.L., Fakhoury, S.A., Moore, M.L., Minnich, M.D., Culp, J.S., DesJarlais, R.L., and Meek, T.D. (1991) Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by oxygen-18 isotope exchange. Biochemistry, 30, 8441-8453.
10. Harte, W.E., Jr. and Beveridge, D.L. (1993) Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation. Journal of the American Chemical Society, 115, 3883-3886;
11. Chen, X. and Tropsha, A., (1995) Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state. Journal of Medicinal Chemistry, 38, 42-48.
12. Wlodawer, A. and Erickson, J.W. (1993) Structure-based inhibitors of HIV-1 protease. Annual Review of Biochemistry, 62, 543-585.
13. Tsantrizos, Y.S. (2008) Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Accounts of Chemical Research, 41, 1252-1263;
14. Debouck, C. and Metcalf, B.W. (1990) Human immunodeficiency virus protease: a target for AIDS therapy. Drug Development Research, 21, 1-17.
15. Roberts, N.A., Martin, J.A., Kinchington, D., Broadhurst, A.V., Craig, J.C., Duncan, I.B., Galpin, S.A., Handa, B.K., Kay, J., Krohn, A., Lambert, R.W., Merrett, J.H., Mills, J.S., Parkes, K.E.B., Redshaw, S., Ritchie, A.J., Taylor, D.L., Thomas, G.J., and Machin, P.J. (1990) Rational design of peptide-based HIV proteinase inhibitors. Science, 248, 358-361.
16. Rich, D.H., Green, J., Toth, M.V., Marshall, G.R., and Kent, S.B.H. (1990) Hydroxyethylamine analogues of the p17/ p24 substrate cleavage site are tightbinding inhibitors of HIV protease. Journal of Medicinal Chemistry, 33, 1285-1288;
17. McQuade, T.J., Tomasselli, A.G., Liu, L., Karacostas, V., Moss, B., Sawyer, T.K., Hendrikson, R.L., and Tarpley, W.G. (1990) A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science, 247, 454-456.
18. Rich, D.H., Sun, C.-Q., Prasad, J.V.N.V., Pathiasseril, A., Toth, M.V., Marshall, G.R., Clare, M., Mueller, R.A., and Houseman, K. (1991) Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. Journal of Medicinal Chemistry, 34, 1222-1225;
19. Krohn, A., Redshaw, S., Ritchie, J.C., Graves, B.J., and Hatada, M.H. (1991) Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxylethylamine isostere. Journal of Medicinal Chemistry, 34, 3340-3342.
20. Swain, A.L., Miller, M.M., Green, J., Rich, D.H., Schneider, J., Kent, S.B., and Wlodawer, A. (1990) X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substratebased hydroxyethylamine inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 87, 8805-8809.
21. Miller, M., Schneider, J., Sathyanarayana, B.K., Toth, M.V.,Marshall, G.R., Clawson, L., Selk, L.,Kent, S.B.H., and Wlodawer, A. (1989) Structure of the complex of synthetic HIV-1 protease with a substratebased inhibitor at 2.3A resolution. Science, 246, 1149-1152.
22. Wlodawer, A. and Erickson, J.W. (1993) Structure-based inhibitors of HIV-1 protease. Annual Review of Biochemistry, 62, 543-585.
23. Ferguson, D.M., Radmer, R.J., and Kollman, P.A. (1991) Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease. Journal of Medicinal Chemistry, 34, 2654-2659;
24. Harte, W.E., Jr. and Beveridge, D.L. (1993) Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation. Journal of the American Chemical Society, 115, 3883-3886.
25. Dohnalek, J., Hasek, J., Duskova, J., Petrokova, H., Hradilek, M., Soucek, M., Konvalinka, J., Brynda, J., Sedlacek, J., and Fabry, M. (2002) Hydroxyethylamine isostere of an HIV-1 protease inhibitor prefers its amine to the hydroxy group in binding to catalytic aspartates. A synchrotron study of HIV-1 protease in complex with a peptidomimetic inhibitor. Journal of Medicinal Chemistry, 45, 1432-1438.
26. Martin, J.L., Begun, J., Schindeler, A., Wickramasinghe, W.A., Alewood, D., Alewood, P.F., Bergman, D.A., Brinkworth, R.I., Abbenante, G., March, D.R., Reid, R.C., and Fairlie, D.P. (1999) Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Biochemistry, 38, 7978-7988.
27. Parkes, K.E.B., Bushnell, D.J., Crackett, P.H., Dunsdon, S.J., Freeman, A.C., Gunn, M.P., Hopkins, R.A., Lambert, R.W.,Martin, J.A.,Merrett, J.H., Redshaw, S., Spurden,W.C., and Thomas, G.J. (1994) Studies toward the large-scale synthesis of the HIV proteinase inhibitor Ro 31-8959. The Journal of Organic Chemistry, 59, 3656-3664;
28. Gohring,W., Gokhale, S., Hilpert, H., Roessler, F., Schlageter, M., and Vogt, P. (1996) Synthesis of the HIV-proteinase inhibitor saquinavir: a challenge for process research. Chimia, 50, 532-537.
29. Ghosh, A.K., Bilcer, G., and Schlitz, G. (2001) Syntheses of FDA approved HIV protease inhibitors. Synthesis, 2203-2229.
30. Wissner, A. (1979) 2-Hetero substituted silylated ketone acetals: reagents for the preparation of a-functionalized methyl ketones from carboxylic acid chlorides. The Journal of Organic Chemistry, 44, 4617-4622.
31. Evans, B.E., Rittle, K.E., Homnick, C.F., Springer, J.P., and Hirshfield, J.A. (1985) Stereocontrolled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides and c-(aminoalkyl) c-lactones. The Journal of Organic Chemistry, 50, 4615-4625.
32. Luly, J.R., Dellaria, J.F., Plattner, J.J., Soderquist, J.L., and Yi, N. (1987) A synthesis of protected aminoalkyl epoxides from a-amino acids. The Journal of Organic Chemistry, 52, 1487-1492.
33. Erickson, J., Neidhart, D.J., VanDrie, J., Kempf, D.J., Wang, X.C., Norbeck, D.W., Plattner, J.J., Rittenhouse, J.W., Turon, M., and Wideburg, N. (1990) Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science, 249, 527-533.
34. Hodge, C.N., Aldrich, P.E., Bacheler, L.T., Chang, C.H., Jadhav, P.K., Korant, B., Lam, P.Y., Maurin, M.B., Meek, J.L., Otto, M.J., Rayner, M.M., Reid, C., Sharpe, T.R., Shum, L., Winslow, D.L., and Erickson-Viitanen, S. (1996) Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chemistry & Biology, 3, 301-314.
35. Bone, R., Vacca, J.P., Anderson, P.S., and Holloway, M.K. (1991) X-ray crystal structure of the HIV protease complex with L-700,417, an inhibitor with pseudo C2 symmetry. Journal of the American Chemical Society, 113, 9382-9384.
36. Hosur, M.V., Bhat, T.N., Kempf, D.J., Baldwin, E.T., Liu, B., Gulnick, S., Wideburg, N.E., Norbeck, D.W., Appelt, K., and Erickson, J.W. (1994) Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 protease. Journal of the American Chemical Society, 116, 847-855.
37. Stuk, T.L., Haight, A.R., Scarpetti, D., Allen, M.S., Menzia, J.A., Robbins, T.A., Parekh, S., Langridge, D.C., Tien, J.-H.J., Pariza, R.J., andKerdesky, F.A.J. (1994)An efficient stereocontrolled strategy for the synthesis of hydroxyethylene dipeptide isosteres. The Journal of Organic Chemistry, 59, 4040-4041.
38. Kempf, D.J., Sham, H.L., Marsh, K.C., Flentge, C.A., Betebenner, D.,Green, B.E., McDonald, E., Vasavanonda, S., Saldivar, A., Wideburg, N.E., Kati, W.M., Ruiz, L., Zhao, C., Fino, L., Patterson, J., Molla, A., Plattner, J.J., and Norbeck, D.W. (1998) Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. Journal of Medicinal Chemistry, 41, 602-617.
39. Kempf, D.J., Marsh, K.C., Denissen, J.F., McDonald, E., Vasavanonda, S., Flentge, C.A.,Green, B.E., Fino, L., Park, C.H., and Kong, X.P. (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proceedings of the National Academy of Sciences of the United States of America, 92, 2484-2488.
40. Fitzgerald, P.M.D., McKeever, B.M., Van Middlesworth, J.F., Springer, J.P., Heimbach, J.C., Leu, C.-T., Herber, W.K., Dixon, R.A.F., and Darke, P.L. (1990) Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0A resolution. The Journal of Biological Chemistry, 265, 14209-14219;
41. Blundell, T.L., Cooper, J., Foundling, S.I., Jones, D.M., Atrash, B., and Szelke, M. (1987) On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition-state analogues. Biochemistry, 26, 5585-5590;
42. Jaskólski, M., Tomasselli, A.G., Sawyer, T.K., Staples, D.G., Heinrikson, R.L., Schneider, J., Kent, S.B.H., and Wlodawer, A. (1991) Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry, 30, 1600-1609.
43. Thaisrivongs, S., Tomasselli, A.G., Moon, J.B.,Hui, J., McQuade, T.J., Turner, S.R., Strohbach, J.W., Howe,W.J., Tarpley, W.G., and Heinrikson, R.L. (1991) Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity. Journal of Medicinal Chemistry, 34, 2344-2356;
44. Thanki, N., Rao, J.K.M., Foundling, S.I., Howe, W.J., Moon, J.B., Hui, J.O., Tomasselli, A.G., Heinrikson, R.L., Thaisrivongs, S., and Wlodawer, A. (1992) Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling. Protein Science: A Publication of the Protein Society, 1, 1061-1072.
45. Vacca, J.P., Guare, J.P., de Solms, S.J., Sanders, W.M., Giuliani, E.A., Young, S.D., Darke, P.L., Zugay, J., Sigal, I.S., Schleif, W.A., Quintero, J.C., Emini, E.A., Anderson, P.S., and Huff, J.R. (1991) L-687,908, a potent hydroxyethylenecontaining HIVprotease inhibitor. Journal of Medicinal Chemistry, 34, 1225-1228.
46. Thompson, W.J., Fitzgerald, P.M.D., Holloway, M.K., Emini, E.A., Darke, P.L., McKeever, B.M., Schleif, W.A., Quintero, J.C., Zugay, J.A., Tucker, T.J., Schwering, J.E., Homnick, C.F., Nunberg, J., Springer, J.P., and Huff, J.R. (1992) Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1 phenyl substituents: X-ray crystal structure assisted design. Journal of Medicinal Chemistry, 35, 1685-1701.
47. Lyle, T.A., Wiscount, C.M., Guare, J.P., Thompson, W.J., Anderson, P.S., Darke, P.L., Zugay, J.A., Emini, E.A., Schleif, W.A., Quintero, J.C., Dixon, R.A.F., Sigal, I.S., andHuff, J.R. (1991) Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. Journal of Medicinal Chemistry, 34, 1228-1230.
48. Dreyer, G.B., Lambert, D.M., Meek, T.D., Carr, T.J., Tomaszek, T.A., Jr., Fernandez, A.V., Bartus, H., Cacciavillani, E., Hassell, A.M., Minnich, M., Petteway, S.R., Jr., Metcalf, B.W., and Lewis, M. (1992) Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell analysis. Biochemistry, 31, 6646-6659;
49. Abdel-Meguid, S.S., Metcalf, B.W., Carr, T.J., Demarsh, P., DesJarlais, R.L., Fisher, S., Green, D.W., Ivanoff, L., Lambert, D.M.,Murthy, K.H.M., Petteway, S.R., Jr., Pitts, W.J., Tomaszek, T.A., Jr., Winborne, E., Zhao, B., Dreyer, G.B., and Meek, T.D. (1994) An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis. Biochemistry, 33, 11671-11677.
50. Hoog, S.S., Towler, E.M., Zhao, B., Doyle, M.L., Debouck, C., and Abdel-Meguid, S.S. (1994) Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity. Biochemistry, 35, 10279-10286.
51. Senanayake, C.H., Smith, G.B., Ryan, K.M., Fredenburgh, L.E., Liu, J., Roberts, F.E., Hughes, D.L., Larsen, R.D., Verhoven, T.R., and Reider, P.J. (1996) The role of 4-(3-phenylpropyl)pyridine N-oxide (P3NO) in the manganesesalen-catalyzed asymmetric epoxidation of indene. Tetrahedron Letters,37, 3271-3274;
52. Jacobsen, E.N., Zhang, W., Muci, A.R., Ecker, J.R., and Deng, L. (1991) Highly enantioselective epoxidation catalysts derived from 1, 2-diaminocyclohexane. Journal of the American Chemical Society, 113, 7063-7064.
53. Senanayake, C.H., Smith, G.B., Ryan, K.M., Fredenburgh, L.E., Liu, J., Roberts, F., Hughes, D.L., Larsen, R.D., Verhoeven, T.R., and Reider, P.J. (1995) The behavior of indene oxide in the ritter reaction: a simple route to cis-aminoindanol. Tetrahedron Letters, 36, 3993-3996;
54. Reider, P.J. (1997) Advances in AIDS chemotherapy: the asymmetric synthesis of crixivan. Chimia, 51, 306-308.
55. Askin, D., Eng, K.K., Rossen, K., Purick, R.M., Wells, K.M., Volante, R.P., and Reider, P.J. (1994) Highly diastereoselective reaction of a chiral, non-racemic amide enolate with (S)-glycidyl tosylate. Synthesis of the orally active HIV-1 protease inhibitor L-735,524. Tetrahedron Letters, 35, 673-676.
56. Vacca, J.P., Dorsey, B.D., Schleif, W.A., Levin, R.B., McDaniel, S.L., Darke, P.L., Zugay, J., Quintero, J.C., Blahy, O.M., Roth, E., Sardana, V.V., Schlabach, A.J., Graham, P.I., Condra, J.H., Gotlib, L., Holloway, M.K., Lin, J., Chen, I.-W., Vastag, K., Ostovic, D., Anderson, P.S., Emini, E.A., and Huff, J.R. (1994) L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 91, 4096-4100.
57. Chen, Z., Li, Y., Chen, E., Hall, D.L., Darke, P.L., Culberson, C., Shafer, J.A., and Kuo, L.C. (1994) Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of HIV proteases. The Journal of Biological Chemistry, 269, 26344-26348.
58. Ghosh, A.K., Thompson, W.J., McKee, S.P., Duong, T.T., Lyle, T.A., Chen, J.C., Darke, P.L., Zugay, J.A., Emini, E.A., Schleif, W.A., Huff, J.R., and Anderson, P.S. (1993) 3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. Journal of Medicinal Chemistry, 36, 292-294;
59. Ghosh, A.K., Thompson, W.J., Lee, H.Y., McKee, S.P.,Munson, P.M., Duong, T.T., Darke, P.L., Zugay, J.A., Emini, E.A., Schleif, W.A., Huff, J.R., and Anderson, P.S. (1993) Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors. Journal of Medicinal Chemistry, 36, 924-927;
60. Ghosh, A.K., Lee, H.Y., Thompson, W.J., Culberson, C., Holloway, M.K., McKee, S.P., Munson, P.M., Duong, T.T., Smith, A.M., Darke, P.L., Zugay, J.A., Emini, E.A., Schleif, W.A., Huff, J.R., and Anderson, P.S. (1994) The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors. Journal of Medicinal Chemistry, 37, 1177-1188.
61. Ghosh, A.K., Thompson, W.J., Munson, P.M., Liu, W., and Huff, J.R. (1995) Cyclic sulfone-3-carboxamides as novel P2-ligands for Ro 31-8959 based HIV-1 protease inhibitors. Bioorganic & Medicinal Chemistry Letters, 5, 83-88.
62. Kaldor, S.W., Appelt, K., Fritz, J.E., Hammond, M., Crowell, T.A., Baxter, A.J., Hatch, S.D., Wiskerchen, M., and Muesing, M.A. (1995) A systematic study of P1-P3 spanning sidechains for the inhibition of HIV-1 protease. Bioorganic & Medicinal Chemistry Letters, 5, 715-720.
63. Kalish, V.J., Tatlock, J.H., Davies, J.F., II, Kaldor, S.W., Dressman, B.A., Reich, S., Pino, M., Nyugen, D., Appelt, K., Musick, L., andWu, B. (1995) Structure-based drug design of nonpeptidic P2 substituents for HIV-1 protease inhibitors. Bioorganic & Medicinal Chemistry Letters, 5, 727-732.
64. The 3-hydroxy-2-methylbenzamide also proved effective when incorporated into scaffolds represented by 38 and 39:
65. Randad, R.S., Lubkowska, L., Bhat, T.N.,Munshi, S.,Gulnick, S.V., Yu, B., and Erickson, J.W. (1995) Symmetry-based HIV protease inhibitors: rational design of 2-methylbenzamides as novel P2/P20 ligands. Bioorganic & Medicinal Chemistry Letters, 5, 1707-1712;
66. Kempf, D.J., Flentge, C.A., Wideburg, N.E., Saldivar, A., Vasavanonda, S., and Norbeck, D.W. (1995) Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease. Bioorganic & Medicinal Chemistry Letters, 5, 2725-2728.
67. Kaldor, S.W., Kalish, V.J., Davies, J.F., II, Shetty, B.V., Fritz, J.E., Appelt, K., Burgess, J.A., Campanale, K.M., Chirgadze, N.Y., Clawson, D.K., Dressman, B.A.,Hatch, S.D., Khalil, D.A., Kosa, M.B., Lubbehusen, P.P., Muesing, M.A., Patick, A.K., Reich, S.H., Su, K.S., and Tatlock, J.H. (1997) Viracept (Nelfinavir Mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. Journal of Medicinal Chemistry, 40, 3979-3985.
68. Reich, S.H. (2001) Discovery and development of nelfinavir (Viracept), in Protease Inhibitors in AIDS Therapy (eds R.C. Ogdenand C.W. Flexner),Marcel Dekker, New York, pp. 85-99.
69. Inaba, T., Birchler, A.G., Yamada, Y., Sagawa, S., Yokota, K., Ando, K., and Uchida, I. (1998) A practical synthesis of nelfinavir, an HIV-protease inhibitor, using a novel chiral C4 building block: (5R,6S)-2,2-dimethyl-5-hydroxy-1,3-dioxepan-6-ylammonium acetate. The Journal of Organic Chemistry, 63, 7582-7583.
70. Beaulieu, P.L., Wernic, D., Abraham, A., Anderson, P.C., Bogri, T., Bousquet, Y., Croteau, G., Guse, I., Lamarre, D., Liard, F., Paris, W., Thibeault, D., Pav, S., and Tong, L., (1997) Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere. Journal of Medicinal Chemistry, 40, 2164-2176.
71. Tung, R.D., Livingston, D.J., Rao, B.G., Kim, E.E., Baker, C.T., Boger, J.S., Chambers, S.P., Deininger, D.D., Dwyer, M., Elsayed, L., Fulghum, J., Li, M., Murcko, M.A., Navia, M.A., Novak, P., Pazhanisamy, S., Stuver, C., and Thomson, J.A. (2001) Design and synthesis of amprenavir, a novel HIV protease inhibitor, in Protease Inhibitors in AIDS Therapy (eds R.C. Ogdenand C.W. Flexner), Marcel Dekker, New York, pp. 101-118.
72. Kim, E.E., Baker, C.T., Dwyer, M.D., Murcko, M.A., Rao, B.G., Tung, R.D., and Navia, M.A. (1995) Crystal structure ofHIV-1 protease in complex withVX-478, a potent and orally bioavailable inhibitor of the enzyme. Journal of the American Chemical Society, 117, 1181-1182.
73. Clair, M.H.S., Millard, J., Rooney, J., Tisdale, N., Parry, N., Sadler, B.M., Blum, M.R., and Painter, G. (1996) In vitro activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Research, 29, 53-56.
74. Coffin, J.M. (1995)HIVpopulation in vivo: implications for genetic variation, pathogenesis and therapy. Science, 267, 483-489.
75. Boden, D., and Markowitz, M., (1998) Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrobial Agents and Chemotherapy, 42, 2775-2783;
76. Mitsuya, H.,Maeda, K., Das, D., and Ghosh, A.K. (2008) Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. Advances in Pharmacology, 56, 169-197;
77. Colman, P.M. (2009) New antivirals and drug resistance. Annual Review of Biochemistry, 78, 95-118.
78. Tisdale, M., Myers, R.E., Maschera, B., Parry, N.R., Oliver, N.M., and Blair, E.D. (1995) Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrobial Agents and Chemotherapy, 39, 1704-1710; 44Maschera, B., Darby, G., Palú, G., Wright, L.L., Tisdale, M., Myers, R., Blair, E.D., and Furfine, E.S. (1996) Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. The Journal of Biological Chemistry, 271, 33231-33235;
79. Maschera, B., Darby, G., Palú, G., Wright, L.L., Tisdale, M., Myers, R., Blair, E.D., and Furfine, E.S. (1996) Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. The Journal of Biological Chemistry, 271, 33231-33235
80. Ermolieff, J., Lin, X., and Tang, J. (1997) Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. Biochemistry, 36, 12364-12370.
81. Roberts, N.A., Charles, C.J., and Sheldon, J. (1998) Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS (London, England), 12, 453-460.
82. Stoica, I., Sadiq, K., and Coveney, P.V. (2008) Rapid and accurate prediction of binding free energies for saquinavirbound HIV-1 proteases. Journal of the American Chemical Society, 130, 2639-2648;
83. Ode, H., Neya, S.,Hata, M., Sugiura, W., and Hoshino, T. (2006) Computational simulations of HIV-1 proteases: multi-drug resistance due to nonactive site mutation L90M. Journal of the American Chemical Society, 128, 7887-7895.
84. Piana, S., Carloni, P., and Rothlisberger, U. (2002) Drug resistance in HIV-1 protease: flexibility-assisted mechanism of compensatory mutations. Protein Science: A Publication of the Protein Society, 11, 2393-2402.
85. Markowitz, M., Mo, H., Kempf, D.J., Norbeck, D.W., Bhat, T.N., Erickson, J.W., and Ho, D.D. (1995) Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. Journal of Virology, 69, 701-706.
86. Gulnick, S.V., Suvorov, L.I., Liu, B., Yu, B., Anderson, B., Mitsuya, H., and Erickson, J.W. (1995) Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry, 34, 9282-9287.
87. Schock, H.B., Garsky, V.M., and Kuo, L.C. (1996) Mutational anatomy of an HIV-1 protease variant conferring crossresistance to protease inhibitors in clinical trials. The Journal of Biological Chemistry, 271, 31957-31963.
88. Patick, A.K., Duran, M., Cao, Y., Shugarts, D., Keller, M.R.,Mazabel, E., Knowles, M., Chapman, S., Kuritzkes, D.R., and Markowitz, M. (1998) Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrobial Agents and Chemotherapy, 42, 2637-2644.
89. Wartha, F., Horn, A.H.C.,Meiselbach, H., and Sticht, H. (2005) Molecular dynamics simulations of HIV-1 protease suggest different mechanisms contributing to drug resistance. Journal of Chemical Theory and Computation, 1, 315-324.
90. Ohtaka, H., Scheon, A., and Friere, E. (2003) Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry, 42, 13659-13666.
91. Condra, J.H., Petropoulos, C.J., Ziermann, R., Schleif, W.A., Shivaprakash, M., and Emini, E. (2000) Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. The Journal of Infectious Diseases, 182, 758-765.
92. Mastrolorenzo, A., Rusconi, S., Scozzafava, A., Barbaro, G., and Supuran, C.T. (2007) Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic acid protease inhibitors. Current Medicinal Chemistry, 14, 2734-2748.
93. Prabu-Jeyabalan, M., Nalivaika, M., and Schiffer, C.A. (2002) Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure (London, England: 1993), 10, 369-381.
94. Thayer, A.M. (2008) New antiretrovirals. Chemical & Engineering News, 86 (38), 29-36.